Has Kerri Bevis, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,111 in general payments to Kerri Bevis, MD across 56 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kerri Bevis, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kerri Bevis, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kerri Bevis, MD

Gynecologic Oncology · Opelika, ALNPI 1003024746

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.5% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for gynecologic oncology clinicians in AL, where the typical reported total is $2,148.

$1,111in general payments, 2019–2025

Across 56 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$196
Daiichi Sankyo Inc.$173
GSK$127
AstraZeneca$85
Pfizer$61
Baxter Healthcare$59
plus $410 from 14 others

What the payments were for

Food & beverage$1,05095%
Education$615%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	8	$196
Daiichi Sankyo Inc.	7	$173
GSK	8	$127
AstraZeneca	5	$85
Pfizer	4	$61
Baxter Healthcare	1	$59
Pharmacyclics LLC, An Abbvie Company	2	$48
Servier Pharmaceuticals LLC	2	$43
Intuitive Surgical	2	$41
Johnson & Johnson	2	$39
Incyte Corporation	2	$38
Regeneron Healthcare Solutions, Inc.	2	$34
Gilead(2 entities)	2	$31
Novartis	2	$30
E.r. Squibb & Sons, L.L.C.	2	$30
Eisai Inc.	1	$20
AbbVie	1	$17
Bristol Myers Squibb	1	$15
Morphosys, US Inc.	1	$14
Pharmacosmos Therapeutics Inc.	1	$12

How this compares

$1,111 in reported general payments places this provider in the 35th percentile of 27 gynecologic oncology providers in Alabama.

See all gynecologic oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$49,964

Medicare patients

105

Services billed

338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
LenvimaLenvatinib Mesylate	28	$646,389
LynparzaOlaparib	35	$419,428
Megestrol Acetate	17	$879
Gabapentin	90	$643
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	36	$527
Prochlorperazine Maleate	39	$461
Ondansetron Hcl	43	$456
Oxycodone Hcl	94	$360
Morphine Sulfate ErMorphine Sulfate	15	$305
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine	16	$284
Tramadol Hcl	61	$282
Celecoxib	43	$261
Levothyroxine Sodium	14	$239
Ibuprofen	44	$221
Ondansetron OdtOndansetron	11	$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Eisai Inc.Lenvima	$20	$646,38928 claims
AstraZenecaLynparza	$85	$419,42835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 27 gynecologic oncology providers in Alabama.

Other gynecologic oncology in Opelika

Charles LeathBirmingham$148K
Rebecca ArendBirmingham$70K
Warner HuhBirmingham$59K
Nathaniel JonesMobile$25K
David DooBirmingham$9K
Michael ToboniBirmingham$8K
Tyler KirbyHuntsville$8K
Frank KellyHuntsville$5K
Jennifer PierceMobile$4K
Margaret LiangBirmingham$3K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →